Zhongyianke Biotechnology Co., Ltd. was established on September 26, 2001 with a registered capital of about CNY368.73 million. Its business scope includes research, development, production and sales of vaccines and their intermediates. It's a high-tech biotechnology company. There are post doctoral research workstation sub station, Tianjin subunit vaccine Innovation Technology Engineering Research Center and Tianjin Key Laboratory of new vaccine research in this company. It has been rated as a national high-tech enterprise, a leading enterprise in Tianjin's strategic emerging industries, a pilot enterprise in the implementation of Tianjin's two modernizations integration management system, and a gazelle enterprise in Tianjin. After confirmation, it was selected into the "ten thousand enterprises and ten thousand people" support plan of Tianjin.
Since its establishment, based on international advanced technology and after more than ten years of continuous investment and research and development, the company has owned an influenza virus subunit vaccine production line with an annual production capacity of 4 million doses, and has the ability to industrialize complex vaccine production technology. At present, the product on the market is "trivalent influenza virus subunit vaccine", which is the first developed product in China. On this basis, the company has independently developed the domestic advanced quadrivalent influenza subunit vaccine with wider immunization, and has applied for relevant patents.
The company attaches great importance to talent gradient construction. It has a complete set of talent selection and employment mechanism for discovering, cultivating and using talents. It not only focuses on the cultivation of internal talents, but also actively seeks and introduces external high-level talents. The enterprise now has 180 employees, including 155 scientific and technological personnel with college degree or above, accounting for 86.1% of the total number of employees; There are 63 scientific and technological personnel directly engaged in research and development, accounting for 35.2% of the total number of employees. At present, the company has 6 vaccine projects under development: 4-valent influenza virus subunit vaccine, serum-free Vero cell rabies vaccine, human diploid rabies vaccine, rubella attenuated live vaccine, 4-valent meningococcal polysaccharide vaccine of group A, C, Y and W135 and recombinant influenza vaccine. So far, the company has applied for  Chinese invention patents,  utility model patents and  copyright.
Adhering to the policy of high-level vaccine research and development, the company is committed to providing safe, high-quality and stable vaccine products for the world, making contribution to human health.